Can Peptides Cause Cancer? The Real Concern and How Physicians Handle It

Growth hormone is released in pulses from the anterior pituitary, mostly overnight, under two opposing controls: growth hormone releasing hormone (GHRH), which stimulates release, and somatostatin, which suppresses it. The ghrelin receptor is a third input that amplifies the pulse.

These products work on that architecture rather than replacing the hormone. Sermorelin is a 29-amino-acid fragment of GHRH. CJC-1295 is a longer-acting GHRH analog; a 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported sustained increases in growth hormone and IGF-1 in healthy adults. Tesamorelin is a stabilized GHRH analog and the only one of the group approved by the FDA, for a specific population. Ipamorelin and hexarelin act at the ghrelin receptor instead, ipamorelin having been characterized in a 1998 European Journal of Endocrinology paper as the first selective growth hormone secretagogue. None is growth hormone — they ask your pituitary for more of your own.

Most of what people mean by growth signalling is downstream of growth hormone. Growth hormone acting on the liver drives insulin-like growth factor 1 (IGF-1), which circulates bound to binding proteins and acts on receptors throughout the body. IGF-1 is the durable, measurable signal, and the number a physician tracks.

At its receptor, two cascades follow. The PI3K–Akt–mTOR arm drives protein synthesis and cell survival, and suppresses apoptosis — the process by which damaged cells normally remove themselves. The Ras–MAPK arm drives proliferation. Both are pathways oncology spends considerable effort trying to switch off, which is the mechanistic root of the concern. The counterweight is that they also repair a tendon, maintain lean tissue and keep skin turning over, and every adult runs them continuously.

The approved tesamorelin labeling puts it in the regulator's own words: the drug "stimulates GH production and increases serum IGF-1, a growth factor," and "the effects of prolonged elevations in IGF-1 levels are unknown."

A secretagogue works through the pituitary, which remains subject to somatostatin feedback and to IGF-1's own negative feedback; a 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported pulsatile secretion persisting during continuous stimulation with CJC-1295. Exogenous IGF-1 bypasses all of that.

It is a meaningful difference, not a guarantee. A secretagogue can still push IGF-1 above your range: the tesamorelin label reports that among patients treated 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3 SDS. Feedback intact is not feedback sufficient, which is why the label instructs monitoring.

Two human situations bracket the question. Acromegaly is decades-long growth hormone and IGF-1 excess from a pituitary tumor, far above anything a prescribed secretagogue produces. A 2018 cohort study and meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled 23 studies and found an overall cancer standardized incidence ratio of 1.5 (95% CI 1.2–1.8); its own Danish cohort of 529 patients gave 1.1 (0.9–1.4), with selection bias noted in earlier single-center studies.

The other bracket is replacement dosing. The KIMS surveillance cohort, reported in the same journal in 2022, followed 15,809 adults with growth hormone deficiency for a mean 5.3 years and found de novo cancer incidence comparable to the general population — standardized incidence ratio 0.92 (95% CI 0.83–1.01). Its limits: observational, a specific diagnosis, roughly five years, and growth hormone rather than a secretagogue.

The observational literature on naturally occurring IGF-1 is larger and points consistently in one direction, with small effect sizes. A 2004 meta-regression in The Lancet reported positive associations between IGF-1 and prostate, colorectal and premenopausal breast cancer. A 2020 analysis in Cancer Research using 394,388 cancer-free UK Biobank participants examined 30 cancer sites at once and found higher IGF-1 associated with colorectal cancer (hazard ratio 1.08 per 5 nmol/L, 95% CI 1.03–1.13), breast (1.11, 1.07–1.15), prostate (1.08, 1.05–1.12) and thyroid cancer (1.18, 1.01–1.37) — and with reduced risks of ovarian and liver cancer. A 2023 collaborative analysis in the International Journal of Epidemiology pooled 20 prospective studies on prostate cancer.

A hazard ratio of 1.08 per 5 nmol/L is a small gradient across the normal range of a hormone everyone has. The consistency across sites is why the mechanism is taken seriously; the magnitude is not what alarm would require.

These are studies of endogenous IGF-1 variation, not of people taking a medication that raises it — that trial has not been run. Association is not causation, and the UK Biobank authors noted that reverse causality cannot be excluded, since an undetected early cancer can influence hormone levels before diagnosis. IGF-1 also correlates with nutrition, body composition, insulin and activity. And the windows are years rather than decades — a gap covered in are peptides safe long term.

BPC-157 has the most explicitly angiogenic literature in this catalog. A 2017 paper in the Journal of Molecular Medicine associated its pro-angiogenic activity with VEGFR2 activation and upregulation; a 2009 paper in the Journal of Physiology and Pharmacology described modulation of angiogenesis in muscle and tendon healing.

All of it is animal and cell work. There are no randomised controlled trials of BPC-157 in humans, and no published tumor signal attributed to BPC-157 in any species. The concern here is mechanistic reasoning, weaker than data in both directions: not evidence of harm, and its absence not evidence of safety.

TB-500 corresponds to the active region of thymosin beta-4, an actin-sequestering protein. The repair literature is substantial: a 1997 FASEB Journal paper described directional migration of human endothelial cells, a 2004 paper in Mechanisms of Ageing and Development described angiogenesis and wound healing, and a 2010 randomized placebo-controlled dose study of intravenous thymosin beta-4 in healthy volunteers, in the Annals of the New York Academy of Sciences, is the main human safety dataset for the parent molecule.

The complication is that cell migration and survival are not tissue-specific, so thymosin beta-4 also appears in the tumor-biology literature. A 2012 review in Critical Reviews in Eukaryotic Gene Expression discussed it as a potential molecular target for tumor therapy, and a 2016 paper in Acta Biochimica et Biophysica Sinica reported that silencing thymosin beta-4 suppressed proliferation and invasion of non-small cell lung cancer cells in vitro. Those are laboratory studies inside cancer cell lines, not studies of TB-500 in a person — but they are why a prescriber asks about cancer history before TB-500 or the BPC-157 + TB-500 preparation.

GHK-Cu carries the oddest citation in this area, better stated than left for someone else to find. The tripeptide was first described by Pickart and Thaler in Nature: New Biology in 1973, in a paper titled "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." That concerned hepatoma cells in culture, half a century ago, before the copper complex now used was characterized. The subsequent GHK-Cu literature — a 2015 paper in BioMed Research International, a 2018 review in the International Journal of Molecular Sciences — is about skin regeneration, collagen and gene expression rather than neoplasia, and GHK-Cu sits in the caution column above because of angiogenesis.

None of the three angiogenic peptides has a published human tumor signal, and none has the long-term human data that would rule one out.

Semaglutide and tirzepatide carry a boxed warning with nothing to do with IGF-1 or angiogenesis, and it is routinely misquoted. The semaglutide text reads: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined." The tirzepatide label is worded identically except that it specifies rats. "In rodents" and "it is unknown whether in humans" are the entire content of the warning.

For semaglutide: a two-year CD-1 mouse study found a statistically significant increase in thyroid C-cell adenomas and a numerical increase in C-cell carcinomas at all dose levels, and a two-year Sprague Dawley rat study found significant increases in C-cell adenomas at all dose levels. The label states human relevance "is unknown and could not be determined by clinical studies or nonclinical studies."

For tirzepatide: a two-year rat study found significant increases in C-cell adenomas, and in adenomas and carcinomas combined; a six-month study in rasH2 transgenic mice found tirzepatide was not tumorigenic. The caveat endocrinologists raise is that rodent thyroid C-cells express GLP-1 receptors at far higher density than human C-cells — an argument the labels do not adopt.

Two large pharmacoepidemiology studies point different ways. A 2023 nested case-control analysis in Diabetes Care, using the French national health insurance database with 2,562 thyroid cancer cases matched to 45,184 controls, reported that one to three years of GLP-1 receptor agonist use was associated with increased risk of all thyroid cancer (adjusted HR 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (1.78, 1.04–3.05).

A 2024 Scandinavian cohort study in The BMJ, covering three countries from 2007 to 2021 with 145,410 GLP-1 initiators against 291,667 DPP-4 inhibitor initiators in an active-comparator new-user design, found no association: hazard ratio 0.93 (95% CI 0.66–1.31) over a mean 3.9 years. The larger, better-controlled study is the null one. Causation in humans is not established, and the studies disagree at the margins.

Both labels state it in the boxed warning: contraindicated in patients with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. Both also say routine monitoring of serum calcitonin or thyroid ultrasound "is of uncertain value" for early detection in treated patients — so the safeguard is history-taking at intake, not a test afterwards. The symptoms the labels direct prescribers to counsel on are a neck mass, difficulty swallowing, shortness of breath and persistent hoarseness. More in is tirzepatide safe.

The first question is whether there is any current or previous malignancy, what type, what treatment and when. "Active" includes disease under surveillance or in treatment, and an unresolved imaging finding or pending biopsy; with active disease, growth-signalling and angiogenic peptides are declined, following the approved labels.

Remission is case-by-case: a hormone-sensitive cancer is considered differently from one that is not, a five-year interval differently from six months. A physician will generally want your oncologist's view, and the answer is often a cautious no, sometimes a yes confined to a molecule without growth or angiogenic mechanisms.

Family history alone is usually not disqualifying. It sharpens which molecule is chosen and how closely IGF-1 is watched, and may move the conversation from IGF-1 LR3 to a secretagogue. The exception is the one the labels name: a family history of medullary thyroid carcinoma, or MEN 2, contraindicates semaglutide and tirzepatide specifically.

A physician should decline to start anything in this category while an unexplained symptom is outstanding: unintended weight loss, drenching night sweats, a lump, a persistent cough, a change in bowel habit, blood where there should not be blood. Overwhelmingly these do not mean cancer; the point is that starting a growth signal is the wrong move while something undiagnosed is being carried. Overdue screening is handled the same way — if a colonoscopy, mammogram, cervical screening or PSA discussion is due, screening comes first.

Two organ-specific checks belong here. Before a GLP-1, thyroid history including the medullary subtype and MEN 2 in the family. Before Melanotan II, a skin assessment: the concern there is pigmentation and existing naevi rather than growth signalling, since a compound that darkens skin can change how a lesion looks. Case reports of melanoma in Melanotan II users appear in the dermatology literature, and a 2017 review in the International Journal of Dermatology covers the risks of unregulated use. A baseline mole check is the reasonable response.

If a growth-axis peptide is prescribed, IGF-1 is measured before the first dose. You cannot interpret a follow-up number without a starting one, and IGF-1 is age- and sex-referenced, reported as a standard deviation score against a range that falls with age.

The target is a physiological range for your age: mid-range, not the top of it. This is the single most important practical safeguard on this page, and a prescriber aiming at the highest IGF-1 a patient will tolerate has inverted the logic. Fasting glucose and HbA1c belong on the same draw, since growth hormone is counter-regulatory to insulin. Follow-up IGF-1 is repeated after the first weeks and periodically after; a number above the age-referenced range triggers a dose reduction, since treatment here is long-term with 28-day refills. A new symptom triggers a conversation regardless of what the labs say.